FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg…
Filed with the SEC on · Summarized by InvestorsBot
FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg for metastatic NSCLC + platinum chemo. CRL cites inspection findings at Catalent Indiana (fill‑finish) as the sole approvability issue. $INCY $NVO 🚨 #Zynyz #FDA #NSCLC
The CRL did not cite Zynyz’s efficacy/safety or the drug substance manufacturer. sBLA was supported by positive Phase 3 POD1UM‑304 data announced Dec 2024. Incyte is working with FDA and Catalent on remediation/resubmission. $INCY 🔁 #POD1UM304 #oncology
Investor note: delay tied to Catalent’s fill‑finish regulatory compliance, not clinical data. Timing depends on Catalent remediation and FDA review—monitor Incyte updates for corrective actions and resubmission plans. $INCY 📌 #biotech #investing